Synopsis
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
48
PharmaCompass offers a list of Colistimethate Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Colistimethate Sodium manufacturer or Colistimethate Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Colistimethate Sodium manufacturer or Colistimethate Sodium supplier.
PharmaCompass also assists you with knowing the Colistimethate Sodium API Price utilized in the formulation of products. Colistimethate Sodium API Price is not always fixed or binding as the Colistimethate Sodium Price is obtained through a variety of data sources. The Colistimethate Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Colimicina manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Colimicina, including repackagers and relabelers. The FDA regulates Colimicina manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Colimicina API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Colimicina manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Colimicina supplier is an individual or a company that provides Colimicina active pharmaceutical ingredient (API) or Colimicina finished formulations upon request. The Colimicina suppliers may include Colimicina API manufacturers, exporters, distributors and traders.
click here to find a list of Colimicina suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Colimicina DMF (Drug Master File) is a document detailing the whole manufacturing process of Colimicina active pharmaceutical ingredient (API) in detail. Different forms of Colimicina DMFs exist exist since differing nations have different regulations, such as Colimicina USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Colimicina DMF submitted to regulatory agencies in the US is known as a USDMF. Colimicina USDMF includes data on Colimicina's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Colimicina USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Colimicina suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Colimicina Drug Master File in Japan (Colimicina JDMF) empowers Colimicina API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Colimicina JDMF during the approval evaluation for pharmaceutical products. At the time of Colimicina JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Colimicina suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Colimicina Drug Master File in Korea (Colimicina KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Colimicina. The MFDS reviews the Colimicina KDMF as part of the drug registration process and uses the information provided in the Colimicina KDMF to evaluate the safety and efficacy of the drug.
After submitting a Colimicina KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Colimicina API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Colimicina suppliers with KDMF on PharmaCompass.
A Colimicina CEP of the European Pharmacopoeia monograph is often referred to as a Colimicina Certificate of Suitability (COS). The purpose of a Colimicina CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Colimicina EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Colimicina to their clients by showing that a Colimicina CEP has been issued for it. The manufacturer submits a Colimicina CEP (COS) as part of the market authorization procedure, and it takes on the role of a Colimicina CEP holder for the record. Additionally, the data presented in the Colimicina CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Colimicina DMF.
A Colimicina CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Colimicina CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Colimicina suppliers with CEP (COS) on PharmaCompass.
A Colimicina written confirmation (Colimicina WC) is an official document issued by a regulatory agency to a Colimicina manufacturer, verifying that the manufacturing facility of a Colimicina active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Colimicina APIs or Colimicina finished pharmaceutical products to another nation, regulatory agencies frequently require a Colimicina WC (written confirmation) as part of the regulatory process.
click here to find a list of Colimicina suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Colimicina as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Colimicina API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Colimicina as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Colimicina and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Colimicina NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Colimicina suppliers with NDC on PharmaCompass.
Colimicina Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Colimicina GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Colimicina GMP manufacturer or Colimicina GMP API supplier for your needs.
A Colimicina CoA (Certificate of Analysis) is a formal document that attests to Colimicina's compliance with Colimicina specifications and serves as a tool for batch-level quality control.
Colimicina CoA mostly includes findings from lab analyses of a specific batch. For each Colimicina CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Colimicina may be tested according to a variety of international standards, such as European Pharmacopoeia (Colimicina EP), Colimicina JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Colimicina USP).
